Fecal immunochemical testing for colorectal cancer and medication restrictions

Abstract

shown in Figure 1. We used longitudinal modeling to calculate the rate of change of different outcomes with increasing EMR, controlling for polyp size and prior resection. We did not control for piecemeal resection because this is related to the endoscopist's resection skill. These results are shown in Table 1. Using this model, we can estimate that it takes 124 EMRs to lower the rate of residual neoplasia to less than 20%. This is a higher number than the 100 EMRs estimated in the original analysis. DISCLOSUREAll authors disclosed no financial relationships relevant to this publication. REFERENCE 1. Bhurwal A, Bartel MJ, Heckman MG, et al. Endoscopic mucosal resection: learning curve for large nonpolypoid colorectal neoplasia. Gastrointest Endosc 2016;84:959-68.e7. http://dx.

Effect of anticoagulants and NSAIDs on accuracy of faecal immunochemical tests (FITs) in colorectal cancer screening: a systematic review and meta-analysis

“…Given the significant proportion of subjects using these drugs and the renewing scientific evidence on this topic, guideline adjustments should be considered. Although this has been an ongoing discussion,37 still no recommendations were made in the latest update of the US Multi-Society Task Force CRC screening guidelines 35…”